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Abstract
Background: Surfactant proteins (SP) are important for the innate host defence and essential for
a physiological lung function. Several linkage and association studies have investigated the genes
coding for different surfactant proteins in the context of pulmonary diseases such as chronic
obstructive pulmonary disease or respiratory distress syndrome of preterm infants. In this study
we tested whether SP-B was in association with two further pulmonary diseases in children, i. e.
severe infections caused by respiratory syncytial virus and bronchial asthma.
Methods: We chose to study five polymorphisms in SP-B: rs2077079 in the promoter region;
rs1130866 leading to the amino acid exchange T131I; rs2040349 in intron 8; rs3024801 leading to
L176F and rs3024809 resulting in R272H. Statistical analyses made use of the Armitage's trend test
for single polymorphisms and FAMHAP and FASTEHPLUS for haplotype analyses.
Results:  The polymorphisms rs3024801 and rs3024809 were not present in our study
populations. The three other polymorphisms were common and in tight linkage disequilibrium with
each other. They did not show association with bronchial asthma or severe RSV infection in the
analyses of single polymorphisms. However, haplotypes analyses revealed association of SP-B with
severe RSV infection (p = 0.034).
Conclusion: Thus our results indicate a possible involvement of SP-B in the genetic predisposition
to severe RSV infections in the German population. In order to determine which of the three
polymorphisms constituting the haplotypes is responsible for the association, further case control
studies on large populations are necessary. Furthermore, functional analysis need to be conducted.
Background
Pulmonary surfactant consists of a lipid and protein com-
plex, that is essential for normal lung function. The lipid
complex lowers the surface tension at the air-liquid inter-
face of the alveolus, and hereby prevents the lung from
collapsing at low lung volume [1]. The protein complex
participates in host defence mechanisms such as regula-
tion of proinflammatory cytokine production, chemo-
taxis, or tissue repair [2]. So far five surfactant proteins
(SP) have been identified in humans: SP-A1, SP-A2, SP-B,
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SP-C and SP-D. SP-A and SP-D are hydrophilic proteins
and mainly involved in the innate immune system,
whereas SP-B and SP-C are hydrophobic and essential
constituents of lung surfactant. All surfactant proteins are
mainly synthesised in the endoplasmic reticulum of alve-
olar type II cells. Because of its diverse functions, derange-
ment in composition, structure, or function of surfactant
proteins may lead to the development of a wide variety of
pulmonary disorders.
Polymorphisms, especially in SP-A and SP-B, have been
associated with lung diseases such as respiratory distress
syndrome in preterm infants (RDS), congenital alveolar
proteinosis (CAP) and chronic obstructive pulmonary dis-
ease (COPD) [3-5]. Furthermore, studies using knockout
mice and clinical studies of human congenital proteinosis
indicate that SP-B defiency is lethal [5].
SP-B is located on the short arm of human chromosome
2, it consists of 11 exons, whereby the 11th exon is not
translated [6]. There are two steps involved in the transla-
tion of SP-B: First, the SP-B transcription product, a 2000
bp long mRNA, is translated into the SP-B preprotein,
which consists of 381 amino acids. Second, two proteo-
lytic reactions take place that remove both the amino ter-
minal and carboxy terminal arm of the proprotein and
lead to the formation of the mature SP-B protein with a
molecular mass of 8 kD [7].
RSV, a single-stranded RNA virus, is involved in at least
70% of cases of infectious infantile bronchiolitis and has
been repetitively linked to asthma. It has been hypothe-
sised that severe RSV infection in infancy might lead to the
development of recurrent wheezing and/or bronchial
asthma, and consequently a common genetic background
of both diseases has been discussed [8-10].
In the present study, we aimed to verify the previously
described polymorphisms in SP-B in the German popula-
tion. Furthermore we were interested in whether any of
these polymorphisms or haplotypes showed association
with severe RSV associated diseases and/or pediatric
asthma. We chose to study five single nucleotide polymor-
phisms (SNP) in SP-B: rs2077079 in the promoter region
(-32G/T); rs1130866 resulting in the amino acid exchange
T131I; rs2040349 in intron 8 (5781A/C); rs3024801
resulting in L176F and rs3024809 resulting in R272H.
Methods
Subjects
Population of infants with severe RSV infection
The population was recruited at the Centre for Pediatrics
and Adolescent Medicine, Freiburg, Germany and at the
Community Children's Hospital of Freiburg, St. Josefs
Hospital. Infants were eligible when hospitalized due to
RSV infection between September 1998 and March 2005.
Infection with RSV was confirmed by antigen test and/or
RSV-specific PCR [11]. According to the case definition
children had symptoms of bronchiolitis, such as wheez-
ing and tachypnea and needed either supplementary oxy-
gen and/or gavage feeding and/or intravenous fluids.
Children with congenital heart defects, immune defi-
ciency, or chromosomal aberrations were excluded. DNA
samples were collected either by blood taking or buccal
smears with sterile cotton sticks. In total 131 children
were included.
Asthmatic population
322 children with asthma (aged 5 to 18 years) were
recruited from the South-Western part of Germany
between July 2000 and January 2005. The patients were
also characterised at the Centre for Pediatrics and Adoles-
cent Medicine, Freiburg, Germany, using a standardized
clinical protocol. An extended medical history was
recorded including occurrence and duration of wheezing
symptoms; previous and acute medications; severity of
previous asthma attacks; previous allergic rhinitis or con-
junctivitis; atopic dermatitis and any family history of
allergic diseases.
The diagnosis was based on a clear-cut history of asth-
matic symptoms, the use of anti-asthmatic medication
and the presence of bronchial hyperreactivity. Bronchial
hyperreactivity was defined as a fall in forced respiratory
volume in one second (FEV1) by at least 15% in hista-
mine testing or exercise provocation using standard proto-
cols [12]. The exact recruitment procedure has been
described in detail previously [13].
Control population
Two hundred and seventy randomly chosen probands
were used as controls (aged 19 to 40 years). They originate
from the same area in the South-Western part of Ger-
many. No medical history was taken and no medical test-
ing was performed on controls.
Genotyping
DNA was extracted from peripheral blood leucocytes, or
buccal smears following standard protocols and column
purified (DNA midikit, Qiagen, Germany). Genotyping
was performed by restriction fragment length polymor-
phism (RFLP). The polymorphisms under investigation
and the conditions for the RFLP analyses (primer pairs,
PCR conditions and restriction enzymes) are given in
table 1.
Sequencing
For each polymorphism three controls (homozygous
wildtype, heterozygous and homozygous mutation) were
sequenced by the dideoxy chain termination method [14]BMC Pulmonary Medicine 2007, 7:6 http://www.biomedcentral.com/1471-2466/7/6
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using the Big Dye Terminator cycle sequencing kit on an
ABI 310 sequencer (Applied Biosystems). All the follow-
ing studies included these reference individuals. In addi-
tion, pool sequencing was performed in order to detect
the presence and allelic frequency of the polymorphism
rs3024809 and rs3024801. The first pool comprises DNA
from 24 asthmatic children and the second pool DNA
from 27 asthmatic children. Thus, a total of 51 asthmatic
children were included.
Statistical analysis
For each SNP association analysis, based on the case-con-
trol design, was performed by using the Armitage's trend
test. This test takes into account the individuals' genotypes
rather than just the alleles, following the guidelines given
by Sasieni [15], as implemented in the program Finetti
(Thomas F. Wienker, unpublished data). The program
Finetti was also used to calculate the Hardy Weinberg
equilibrium (HWE) for each polymorphism in all popula-
tions. In addition, we performed haplotype frequency
estimations with the programs FASTEHPLUS [16] and
FAMHAP [17]. The extent of linkage disequilibrium
between the polymorphisms has been calculated using
the Arlequin program.
Approval
The collection of blood and the experimental procedures
were approved by the Ethical Committee of the University
of Freiburg. A statement of informed consent was signed




Three polymorphisms – rs 2077079, rs1130866 and
rs2040349 – were genotyped on 131 children with severe
RSV infection, 270 controls and 322 asthmatic children.
All polymorphisms were in Hardy Weinberg equilibrium
in all populations (data not shown). Thus a systematic
genotyping error or population stratification seems to be
unlikely. In order to detect the occurrence and allelic fre-
quency of the previously described polymorphisms
rs3024809 and rs3024801 in our populations we per-
formed pool sequencing. However, for both SNPs only
the wild type was detectable in both pools. Thus, the pol-
ymorphisms seem to be very rare in our German popula-
tion and were not investigated further.
Association studies
The positions of the SNPs and the p-values for association
with severe RSV infection and bronchial asthma obtained
by Armitage's trend test are listed in table 2. None of the
evaluated polymorphisms showed association with either
disease.
Haplotype analyses and linkage disequilibrium
All polymorphisms were in tight linkage disequilibrium
to each other in all populations (data not shown). The
haplotypes occurring in the populations are listed in table
3. By typing three polymorphisms 23 haplotypes are theo-
retically possible; all of these exist in our populations. No
significant differences in haplotype distribution were
apparent between controls and the asthmatic population.
In contrast, the haplotype distribution differed between
Table 2: Polymorphisms under investigation
Polymorphism Position RSV Asthma controls RSV- controls asthma- controls asthma- RSV
rs2077079 -32G/T 48; 56; 22 117; 139; 43 90; 137; 36 0.989 0.461 0.578
rs1130866 T131I 25; 70; 33 78; 133; 97 64; 126; 79 0.930 0.924 0.992
rs2040349 5781A/C 63; 69; 13 134; 139; 36 110; 116; 33 0.491 0.727 0.677
Genotype distribution in the populations (in the following order: homozygous wildtype, heterozygous, homozygous mutation). The p-value for 
association is listed as given by Armitage's trend test.
Table 1: Primers, PCR conditions and restriction enzymes used for genotyping
Polymorphism Primer PCR condition Restriction enzyme
rs 2077079 AGCCACAAGTCCAGGAACAT 
ATGCCTAGCACAAAGCAGTG
65°-55°C in -0.5°C steps, 20 cycles, 55°C 24 cycles 3U BSI1
rs 1130866 TGGGGGATTAGGGGTCAGTC 
CCATGGGTGGGCACAGGGG
65°-55°C in -0.5°C steps, 20 cycles, 55°C 20 cycles 1U TaaI
rs2040349 GACACTGGAGACGGAGGACT 
AAAGCCAGCTGATGCTCTTC
65°-55°C in -0.5°C steps, 20 cycles, 55°C 20 cycles 1U NIaIV
rs 3024801 CCTAACACTCCCACCCTGTG 
TCCTCCCCTCTCTCTTCCTC
65°-55°C in -0.5°C steps, 20 cycles, 55°C 20 cycles pool sequencing
rs 3024809 GCTACTCCGTCATCCTGCTC 
GCCCATACCTTTTCCCTGTC
65°-55°C in -0.5°C steps, 20 cycles, 55°C 20 cycles pool sequencingBMC Pulmonary Medicine 2007, 7:6 http://www.biomedcentral.com/1471-2466/7/6
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the RSV population and controls. The most distinct differ-
ence was found for the haplotype bearing the wild type
allele for all three polymorphisms (frequency of 0,23 in
controls compared to 0,14 in the RSV population). The
haplotype bearing two wildtype alleles and a mutated
allele also showed a marked difference between the pop-
ulations (see Table 3).
Table 4 shows the results of haplotype analyses as calcu-
lated by FAMHAP and FASTEHP. Haplotypes were associ-
ated with severe RSV infection by p = 0,034 (FAMHAP)
and p = 0,035 (FASTEHPLUS). In contrast, no association
with bronchial asthma was detected.
Discussion
Surfactant proteins play important roles in the mainte-
nance of normal lung function and host defence. Acute or
chronic inflammation may lead to local alteration of SP
concentrations. Our study focussed on the genetic varia-
bility of these proteins in an attempt to identify children
at increased risk for inflammatory lung disease like severe
RSV infection and bronchial asthma. Thus the aim was to
determine, whether polymorphisms within SP-B  show
association with one or both diseases. Furthermore, we
were interested to detect a common genetic link between
both diseases – as has previously been discussed [8-10].
However, we did not find any association of three com-
mon SP-B polymorphisms neither with severe RSV infec-
tions nor with bronchial asthma. In addition, haplotype
analysis of the asthmatic population supported further
that SP-B polymorphisms do not play a major role in the
development of asthma. This is an important point
according to the biophysical and immunological proper-
ties of surfactant proteins in lung development and func-
tion [18]. Hohlfeld and colleagues demonstrated
alteration of all SPs (SP-A, SP-B, SP-C and SP-D) in the
bronchoalveolar lavage after segmental allergen challenge
in patients with asthma. In addition, they assume that
activation of the surfactant system is not a universal
response to airway inflammation, but rather a specific
response to the disturbance of surfactant function by aller-
gen challenges [19].
Haplotype analysis of the three SP-B polymorphisms in
the RSV population suggests an influence of these SNPs
on the genetic predisposition to severe RSV infection (p =
0.034 and p = 0.035, respectively). Interestingly, we have
already described association of Surfactant protein C with
RSV bronchitis in the same cohort [20]. This might further
emphasis the importance of the Surfactant system in RSV
bronchiolitis. However, looking at the haplotype distribu-
tion, it is not possible to decide which haplotype may be
the most important one in the development of severe RSV
infections. Here functional studies are clearly needed.
This is the first analysis of SP-B polymorphisms in RSV
associated diseases. Previous studies have implicated SP-B
polymorphisms as contributing factors to RDS [21],
COPD and acute respiratory failure [22]. In the majority
of published studies the amino acid variant T131I is asso-
ciated with increased risk to pulmonary diseases. Interest-
ingly, the amino acid change T131I leads to the block of
the N-glycosylation site [23]. This change may have an
impact on SP-processing and/or on the function of SP-B.
Nevertheless, we did not find association of T131I with
severe RSV infection. This could be due to the small sam-
ple size of our RSV population. Still our population is
larger than the ones used in the above mentioned studies.
In addition, we performed power calculations to test the
validity of our results. In our asthmatic population with
322 individuals the power to find association with asthma
(p-value of p = 0.05, assuming a relative risk of the variant
of 2) is between 0.94 for rs2077079 and 0.97 for
rs2040349. Regarding the RSV population the power is
slightly lower due to the smaller sample size (0.83 to
0.88).
The polymorphisms rs2077079 did not show association
with asthma or severe RSV infection in our populations.
One previous study evaluated this polymorphism in a
population with RDS and reported association of this pol-
ymorphism with RDS in black subjects [21]. However, the
population size was too small to yield significant results.
No significant association was observed between the SNP
and RDS in the white population. This is in line with our
results. As so little is known about the functional impact
Table 4: Results of the haplotype analyses using the programs 
FAMHAP and FASTEHP
RSV-controls Asthma-Controls RSV-asthma
FAMHAP 0,034 0,396 0,12
FASTEHP 0,035 0,364 0,09
Table 3: Haplotypes in the three populations under investigation
Haplotype RSV Controls Asthma
111 0,15 0,23 0,21
112 0,13 0,06 0,10
121 0,23 0,17 0,22
122 0,08 0,13 0,09
211 0,17 0,13 0,11
212 0,00 0,05 0,04
221 0,13 0,11 0,12
222 0,12 0,11 0,10
1 = wildtype, 2 = mutation. The polymorphisms are listed in the 
following order: rs2040349, rs1130866 and rs2077079.BMC Pulmonary Medicine 2007, 7:6 http://www.biomedcentral.com/1471-2466/7/6
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of this SNP, we can only speculate about its role in haplo-
type distribution.
Conclusion
In conclusion, our results indicate a possible association
of SP-B haplotypes with severe RSV infection in the Ger-
man population. In order to determine which one or ones
of the three polymorphisms forming the haplotypes is/are
responsible for the association, further case control stud-
ies on large populations are necessary. Furthermore, func-
tional analysis needs to be conducted.
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